2833 Smith Avenue
Suite 333
Baltimore, MD 21209
United States
443 738 4051
https://www.gcanrx.com
Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 1
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Aitan Zacharin | Chairman, President, CEO, Acting CFO & Treasurer | 120k | N/A | 1983 |
Motti Stenge | Chief Operating Officer | N/A | N/A | N/A |
Dr. Adi Aran M.D. | Chief Scientific Advisor | N/A | N/A | N/A |
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The Greater Cannabis Company, Inc. was founded in 2014 and is based in Baltimore, Maryland.
The Greater Cannabis Company, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.